Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080340 · ClinicalTrials.gov registry record · Phase 3
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small-Cell Lung Carcinoma, sponsored by Telik.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT00080340 is a Phase 3 study of Non-Small-Cell Lung Carcinoma that has completed, run by Telik. The registered enrollment target is 520 participants, above the 218-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00080340, a Phase 3 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG TLK286 (Telcyta) HCl for Injection
- DRUG gefitinib (Iressa)
Study Locations (20)
California
- East Bay Medical Oncology/Hematology Medical Associates, Inc. - Antioch
- East Valley Hematology Oncology Medical Group - Burbank
- Providence Saint Joseph Medical Center - Burbank
- Marilyn Norton, M. D. - Chula Vista
- Rosalba Rodriquez, M. D. - Chula Vista
- Bay Area Cancer Research Group - Concord
- Wilshire Oncology Medical Group, Inc. - Glendora
- Grossmont Hospital - La Mesa
- Sharp Rees-Stealy - La Mesa
Arkansas
- Little Rock Hematology Oncology Benton - Benton
- Highlands Oncology Group - Bentonville
- Highlands Oncology Group - Fayetteville
- Heritage Physician Group, Oncology - Hot Springs
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Springdale
Alabama
- UAB CCC Clinical Studies Unit - Birmingham
- Department of Veterans Affairs Medical Center - Birmingham
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Palo Verde Hematology Oncology - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080340
The ClinicalTrials.gov registry entry for NCT00080340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (139% higher). The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which TLK286 (Telcyta) HCl for Injection is the first listed.
NCT00080340 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00080340 about?
NCT00080340 is a clinical study titled "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
What is the current status of trial NCT00080340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. Estimated completion is 2005-05.
What conditions does trial NCT00080340 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00080340?
The interventions under investigation include: TLK286 (Telcyta) HCl for Injection (DRUG), gefitinib (Iressa) (DRUG).
Who is sponsoring clinical trial NCT00080340?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080340 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
COMPLETED · Phase 3
-
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 3
-
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
COMPLETED · Phase 3
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.